CordenPharma Expands Peptide Platform with >€500m Greenfield Facility Construction

• CordenPharma has announced a >€1 billion investment in peptide development and manufacturing, with a >€500 million new facility in Muttenz, Switzerland.

• The expansion includes increased production capacity in Boulder, Colorado, and aims to surpass €1 billion in sales by 2028.

CordenPharma has unveiled a strategic >€1 billion investment to expand its peptide development and manufacturing capabilities, aiming to exceed €1 billion in sales by 2028. A key component of this plan is a >€500 million facility in Muttenz, Switzerland, designed to enhance its peptide manufacturing capacity and reinforce its presence in the contract manufacturing sector.

The new Swiss facility will be located in Getec Park, just outside Basel, a major European biotech and pharma hub. The site was chosen for its efficient infrastructure, access to skilled talent, and sustainable operational advantages. The facility will house multiple production lines, with solid-phase peptide synthesis (SPPS) reactors exceeding 5,000 litres in total capacity. The main construction phase is set for 2025 to 2027, with commercial operations beginning in 2028, generating 300 new jobs in the region.

Parallel to this development, CordenPharma Colorado in Boulder, USA, is undergoing expansion. The site’s SPPS reactor capacity will more than double to over 42,000 litres by 2028, strengthening CordenPharma’s global peptide production capabilities.

Dr. Michael Quirmbach, President & CEO of CordenPharma Group, stated: “We are excited to announce the construction of a state-of-the-art manufacturing plant just outside Basel, Switzerland, within one of the leading pharma and biotech hubs in Europe.”

CordenPharma was acquired by Astorg, a Pan-European private equity firm, in 2022. With Astorg’s support, these investments are set to position CordenPharma as a major CDMO for peptide-based medicines, meeting rising market demand and expanding global access to peptide therapies.